Likewise, in NSCLC cells resistant to molecularly-targeted therapies (EGFR-TKI, ALK inhibitor Crizotinib, and MEK inhibitor Selumetinib), OSM/JAK1/STAT3–signaling protects cells from targeted drug-induced apoptosis [190]. Here, STAT3 is linked to non-small cell lung carcinoma.